|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 中年成人平均动脉压的体位改变与动脉硬度的关系:Framingham心脏研究显示文摘Torjesen A, Cooper LL, Rong J, Larson MG, Hamburg NM, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Relations of arterial stiffness with postural change in mean arterial pressure in middle-aged adults:the Framingham heart study. Hyperten- sion,2017,69(4) :685-690.站立位血压稳定调节受损可导致不良结果,包括跌倒、晕厥和定向障碍。平均动脉压(meanarterialpressure,MAP)通常在站立位时增加,然而,站立位MAP增加不足或减少可能导致脑灌注减少。已有研究报道,在动脉硬度增加的老年人中存在体位性低血压,年轻至中年人MAP的体位性改变与动脉硬度的相关性尚未阐明。该研究分析了Framingham心脏研究第3代队列中的受试者3205人(女性1693人,占53%)的直立性血压反应和全面血液动力学数据。 | Torjesen A Cooper LL Rong J Larson MG Hamburg NM Levy D Benjamin EJ Vasan RS Mitchell GF 刘莉 叶鹏 | 2017 | 中华高血压杂志2017，25，3： | 5 |
| 2 | Cilostazol for secondary stroke prevention:systematic review and meta-analysis显示文摘Background Stroke is one of the leading causes of death worldwide.Cilostazol,an antiplatelet and phosphodiesterase 3 inhibitor,has not been clearly established for ischaemic stroke use.We aim to determine the efficacy and safety of cilostazol for secondary stroke prevention.Methods MEDLINE,EMBASE,Cochrane Library,Web of Science and ClinicalTrials.gov were searched from inception to 25 September 2020,for randomised trials comparing the efficacy and safety of cilostazol monotherapy or dual therapy with another antiplatelet regimen or placebo,in patients with ischaemic stroke.Version 2 of the Cochrane risk-of-bias tool for randomised trials(RoB 2)was used to assess study quality.This meta-analysis was reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA)statement.Results Eighteen randomised trials comprising 11429 participants were included in this meta-analysis.Most trials possessed low risk of bias and were of low heterogeneity.Cilostazol significantly reduced the rate of ischaemic stroke recurrence(risk ratio,RR=0.69,95%CI 0.58 to 0.81),any stroke recurrence(RR=0.64,95%CI 0.54 to 0.74)and major adverse cardiovascular events(RR=0.67,95%CI 0.56 to 0.81).Cilostazol did not significantly decrease mortality(RR=0.90,95%CI 0.64 to 1.25)or increase the rate of good functional outcome(Modified Rankin Scale score of 0–1;RR=1.07,95%CI 0.95 to 1.19).Cilostazol demonstrated favourable safety profile,significantly reducing the risk of intracranial haemorrhage(RR=0.46,95%CI 0.31 to 0.68)and major haemorrhagic events(RR=0.49,95%CI 0.34 to 0.70).Conclusions Cilostazol demonstrated superior efficacy and safety profiles compared with traditional antiplatelet regimens such as aspirin and clopidogrel for secondary stroke prevention but does not appear to affect functional outcomes.Future randomised trials can be conducted outside East Asia,or compare cilostazol with a wider range of antiplatelet agents. | Choon Han Tan Andrew GR Wu Ching-Hui Sia Aloysius ST Leow Bernard PL Chan Vijay Kumar Sharma Leonard LL Yeo Benjamin YQ Tan | 2021 | Stroke & Vascular Neurology2021，6，3： | 2 |
| 3 | Monitoring the influence of different weathering conditions on polyethylene pipes by IR-microscopy显示文摘 | Raquel Maria Karsten Rode Robert Brüll Frank Dorbath Benjamin Baudrit Martin Bastian Emmanuelle Brendlé | 2011 | Polymer Degradation and Stability2011，，10： | 1 |
| 4 | Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential 显示文摘 | Alexandra P Jason AM Benjamin LL | 2004 | Blood2004，103，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员